News All PostNewsCiriaco Maraschiello joins Axxam as Chief Operating Officer5 July 2023read more >Uwe Gottschalk appointed as Board Observer15 June 2023read more >Jörg Hüser joins Axxam as Chief Scientific Officer1 June 2023read more >Axxam and Promega announce agreement to develop smart assays for drug discovery services24 May 2023read more >Keensight Capital to acquire a majority stake in Axxam, a leading European partner research organization in life sciences28 July 2022read more >Axxam S.p.A. announces the merger of its two German subsidiaries into Axxam GmbH12 January 2022read more >Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative…9 July 2021read more >Axxam is a member of the REsolution consortium10 June 2021read more >Axxam acquires Hit Discovery Constance27 May 2021read more >Symegold library for drug discovery services9 December 2020read more >Old
Axxam and Promega announce agreement to develop smart assays for drug discovery services24 May 2023read more >
Keensight Capital to acquire a majority stake in Axxam, a leading European partner research organization in life sciences28 July 2022read more >
Axxam S.p.A. announces the merger of its two German subsidiaries into Axxam GmbH12 January 2022read more >
Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative…9 July 2021read more >
